英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
kunwari查看　kunwari　在百度字典中的解释百度英翻中〔查看〕
kunwari查看　kunwari　在Google字典中的解释Google英翻中〔查看〕
kunwari查看　kunwari　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
    Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years
  • Model-Based Meta-Analysis of IL-17 A Inhibitors for Moderate . . . - Springer
    Biologics targeting IL-17 A demonstrate rapid therapeutic efficacy, durable long-term outcomes, and favorable safety profiles, addressing patients’ need for prompt skin lesion resolution At present, the FDA and EMA have approved three IL-17 A inhibitors: secukinumab, ixekizumab and bimekizumab
  • Emerging Oral Therapies for the Treatment of Psoriasis: A Review of . . .
    The introduction of biologic agents for the treatment of psoriasis has revolutionized the current treatment landscape, targeting cytokines in the interleukin (IL)-23 IL-17 pathway and demonstrating strong efficacy and safety profiles in clinical trials
  • Study Details | NCT07038720 | A Study of UA026 Tablets in Healthy Adult . . .
    This first-in-human study assessed the safety, tolerability, pharmacokinetics (PKs), and biomarkers including circulating IL-17A target engagement profile of single or multiple oral doses of the UA026 in healthy subject and subjects with moderate to severe plaque psoriasis
  • A Closer Look at IL-17 Inhibitors in Psoriasis
    IL-17 inhibitors differ in targeting IL-17A, IL-17RA, or IL-17A F, impacting efficacy and safety These agents offer rapid skin clearance, improve patients’ quality of life, and require patient-specific selection based on clinical and real-world factors, including dosing, safety, and long-term data
  • Safety Profiles of Biologic Drugs in Psoriasis and Psoriatic Arthritis
    This chapter provides a comprehensive review of the safety profiles of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), including TNF-α, IL-17, IL-12 23, and IL-23 inhibitors, and Janus kinase (JAK) and PDE-4 inhibitors
  • Evaluating the Safety Profile of IL-17 Inhibitors in Psoriatic Disease
    The experts explain that IL-17 therapies are generally well tolerated and offer a favorable safety profile compared with older systemic agents like TNF inhibitors and methotrexate, which require frequent lab monitoring
  • Comparative efficacy and safety of IL-17 and IL-23 inhibitors for . . .
    This systematic review and meta-analysis evaluate the efficacy and safety of IL-17 and IL-23 inhibitors in East Asian adults with moderate-to-severe plaque psoriasis, using data from randomized controlled trials published between 2019 and 2025
  • Update on IL-17 Inhibitors for Psoriasis - Springer
    Data suggests IL-17 inhibitors are efficacious and safe for use in patients with psoriasis Patient non-adherence to taking daily pills or failed therapy with older systemic agents may be indications for the use of IL-17 inhibitors in patients with psoriasis
  • Clinical proof of concept for small molecule mediated inhibition of IL . . .
    Efficacious and well-tolerated systemic, oral treatments for psoriasis are needed We report preclinical and phase 1c (NCT06808815) results for DC-806, a small molecule interleukin (IL)-17 inhibitor, for the treatment of mild-to-moderate psoriasis Preclinical results demonstrated DC-806 targets IL-17AA and IL-17AF with secukinumab-like therapeutic efficacy In the phase 1c trial, 32 patients





中文字典-英文字典  2005-2009